Trinity Investors proudly announces a significant milestone achieved by portfolio company Nuclein, LLC, a pioneer in rapid, point-of-care molecular diagnostics.
Nuclein has secured U.S. Food and Drug Administration (FDA) 510(k) clearance and a Clinical Laboratory Improvement Amendments (CLIA) waiver for its DASH® SARS-CoV-2 & Flu A/B Test, designed for use on the groundbreaking DASH® Rapid PCR System.
To read the full press release, please click here.
